Josef Newgarden returns to the center stage at Fox Sports marketing ahead of the 2026 season, with the first in their ...

Both Skyrizi and its cousin Rinvoq have landed in the annual top three, in varying positions, since 2022. That was once again the case in 2025, when Skyrizi retained its place at the top and Rinvoq ...

Lynk Pharmaceuticals’ next generation JAK inhibitor, zemprocitinib, has met its primary and secondary trial endpoints during a Phase III study in rheumatoid arthritis. Image credit: one photo via ...

New York has enacted the 2022 Uniform Commercial Code (UCC) Amendments, introducing Article 12 and key Article 9 updates that modernize commercial law for digital assets and clarify how interests in ...

AbbVie raised its dividend for 13 straight years with a 13% CAGR over the past decade. The current yield stands at 2.9%. Skyrizi and Rinvoq are projected to reach $31B in combined sales by 2027. The ...

AbbVie said a pair of late-stage study of its blockbuster autoimmune drug Rinvoq hit their main goals in the chronic autoimmune disease vitiligo. AbbVie on Wednesday said the replicate Phase 3 studies ...

The $1.25 billion refinancing of 3 Bryant Park last February wasn’t only good news for owner Ivanhoe Cambridge and the 1.2 million square-foot office tower. Drew Isaacson, part of the JLL capital ...

The updated indications state that if TNF blockers are clinically inadvisable, patients may still be administered Rinvoq if they have previously received at least 1 approved systemic therapy. The Food ...

The Food & Drug Administration granted AbbVie expanded approval for its Rinvoq drug intended to treat moderately to severely active ulcerative colitis and moderately to severely active Crohn's disease ...

From sales to compliance, AI agents promise to augment workforce capabilities, streamline workflows, and enhance productivity. In association withGlobant Amid the turbulence of the wider global ...

Shares of AbbVie ABBV rose over 4% to a record high on Thursday after the company announced that it had settled patent litigation with all generic manufacturers who had sought the FDA’s approval for ...